ALK+ Blog/News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
PATIENT SPOTLIGHT: Andrej Krivda, Wettingen, Switzerland
We interviewed fellow ALKie Andrej Krivda on his very interesting journey with ALK+ lung cancer and all the unexpected twists and turns he’s had to navigate since diagnosis. Andrej is the very first person to enter the Nuvalent NVL-655 clinical trial in Spain and one of the first patients to take part in the trial…
-
Healthy Recipe: Salmon Piccata over Pasta
Our “Practical Chef” and fellow ALKie, Juli Posner shares one of her favorite healthy recipes. “I love Salmon, and I love lemon. This quick fancy ,but easy, recipe incorporates both. Crispy pan Sautéed Salmon tossed in a quick lemon butter sauce will give you a restaurant worthy dinner that is on the table in less…
-
Introducing ALK Positive Italia An interview with Founder, Patty Saccenti
ALK Positive, Inc has introduced a section in our newsletter to feature international (non-US) ALK patient groups/organizations. If you would like your group/organization to be featured in a future newsletter, please contact Duncan Preece at duncan.preece@alkpositive.org In this issue, we are introducing ALK Positive Italia and have interviewed the founder, Patty Saccenti.
-
Pearl Couscous and Lentil Salad Recipe By chef, fellow ALKie, Juli Posner
This salad is so colorful and fresh, it looks gorgeous on any buffet table. It can be a side, yet it doubles as the main event if you add your favorite protein! (Shrimp works beautifully). With lots of texture from crunchy cucumbers, salty brininess from Kalamata olives, and sweetness from golden raisins, it’s a virtual…
-
The New ALK Inhibitor: NVL-655 Trial Expands to Europe!
Who is this trial for: NVL-655 is a 4th generation, brain-penetrant, ALK TKI inhibitor created to overcome several limitations observed with currently available therapies. NVL-655 is designed to have activity in tumors that have developed resistance to first, second, and third-generation ALK inhibitors, including tumors with the solvent front G1202R mutation or compound mutations G1202R/L1196M…
-
ALK Positive and LUNGevity Foundation Announce Recipients of the 2022 ALK-Positive Research Awards
To transform advanced ALK-positive lung cancer into a chronic or curable disease, ALK Positive to award $1.75 million through their research award program WASHINGTON, DC (December 1, 2022)— Patient organization ALK Positive, in partnership with LUNGevity Foundation, announced the 2022 recipients of the ALK Positive/LUNGevity ALK-Positive Lung Cancer Research Awards. The grant monies, totaling $1.75…
-
Groups Award Two Grants for ALK-positive Lung Cancer Research
(December 28, 2022) – ALK Positive Inc. (ALK Positive) and The Lung Cancer Research Foundation (LCRF) announce funding of two ALK-positive related lung cancer projects. These grants, totaling $500,000, are awarded to researchers whose projects are focused upon transforming care and improving outcomes for patients with ALK-positive non-small cell lung cancer (NSCLC). “This is an…
-
Moderna’s Cancer Vaccine Program
Highly successful Covid vaccines have raised the question of ‘why not cancer vaccines?’, a question of great interest and financial contribution for the ALK Positive NSCLC community in recent years. Somewhat under the radar of our members is Moderna, Inc.’s multi-cancer clinical trial for their personalized mRNA vaccine that started in 2017. The trial is…
-
WE NEED YOUR INFO: Take part in our longitudinal survey of ALK+ Cancer Patients
More participants = more data = better research = more life!We invite you to complete a patient survey/registry specific to ALK-positive lung cancer. This is an IRB approved professionally study conducted by researchers at University of Washington and paid for by ALK Positive Inc. All data is de-identified, and will inform oncologists, researchers, patients and…
-
The New ALK Inhibitor: NVL-655 Expands Clinical Trial Sites
Who is this trial for: NVL-655 is a 4th generation, brain-penetrant, ALK TKI inhibitor created to overcome several limitations observed with currently available therapies. NVL-655 is designed to have activity in tumors that have developed resistance to first, second, and third-generation ALK inhibitors, including tumors with the solvent front G1202R mutation or compound mutations G1202R/L1196M…
-
Hearty Fall Vegetable Soup Recipe by Chef and Fellow ALKie, Juli Posner
With the cold weather upon us ( and the holidays right around the corner), I love making a one-pot meal that’s great the “day of”, and only gets better day-by-day….. That is, if your family doesn’t devour it in one sitting! Having it be super healthy is an extra added bonus! For this soup, which is…
-
PATIENT SPOTLIGHT: Debbi Martinez, New Jersey, USA
Member and fellow ALKie Debbi Martinez is the volunteer working behind the scenes with ALK Positive’s Kindful fundraising platform and doing a great job at that. For this year’s Lung Cancer Awareness Month, we wanted to honor a volunteer that is not visible by being at the forefront of operations, but is just as invaluable…